Trial opens to evaluate experimental cancer drug against solid tumors

Posted: Aug 2, 2017

Chemotherapy drugs have long been the mainstay of treatment for advanced solid tumors, but the toxic side effects of these drugs often limit the amount that can safely be given to patients. Doctors hope that PEN-866, an experimental cancer drug, can help to overcome this difficulty. Anish Thomas, M.D., who is leading this new trial, says, “This is a first-of-its-kind approach to facilitate tumor targeted delivery of chemotherapy drugs, which, if successful, would be a big step forward for cancer therapy.” Learn more...

Trial opens to evaluate experimental cancer drug against solid tumors

New clinical trial will test immunotherapy for type of HPV infection

Posted: Aug 1, 2017

Vulvar high-grade squamous intraepithelial lesion (HSIL) is caused by chronic infection with the human papillomavirus (HPV) type 16. Patients with vulvar HSIL have an increased risk of developing cancer. Lesions are usually treated surgically. However, the vulvar lesions commonly recur because of persistent systemic infection with HPV. Christian Hinrichs, M.D., a Lasker Clinical Research Scholar in the Experimental Transplantation and Immunology Branch is leading a study of a systemic immunotherapy directed at killing the HPV infection causing vulvar HSIL. Read more...

New clinical trial will test immunotherapy for type of HPV infection
microscope

A new imaging technique to detect recurrent prostate cancer is tested in new clinical trial

Posted: Jul 26, 2017

Standard imaging techniques cannot accurately locate sites of prostate cancer metastasis. The use of 18F-DCFPyL, a second-generation PET agent, aims to improve doctors’ ability to assess high-risk primary tumors, detect sites of recurrent prostate cancer and target therapies to specific sites of recurrence. Read more...

A new imaging technique to detect recurrent prostate cancer is tested in new clinical trial

Surgery Branch recruiting patients to study new treatment for cancers with RAS mutations

Posted: Jul 5, 2017

RAS is a family of proteins that send signals to genes involved in cell growth and is mutated in approximately a quarter of all human cancers. James Yang, M.D., of the Surgery Branch is leading a team of investigators who have generated a special T-cell receptor from mouse cells that can recognize a mutation of RAS that is found in many human cancer cells. The goal is to determine if a new therapy is safe and can help shrink tumors that have the G12V RAS mutation. Read more...

Surgery Branch recruiting patients to study new treatment for cancers with RAS mutations

Using radioactive drugs could lead to better imaging of prostate cancer

Posted: Jun 30, 2017

Medical imaging (x-ray, ultrasound, MRI, CT, PET scan) is a noninvasive way to view the internal structures of the body. However, these tools are not ideal for detecting cancer that has spread, or metastasized, because the precise location of these cancer cells is unknown. Researchers are now testing an experimental radiotracer called 18F-DCFPyL to help find sites of cancer in the body.  Learn more...

Using radioactive drugs could lead to better imaging of prostate cancer

New clinical trial studies the addition of immunotherapy to chemotherapy for patients with biliary tract carcinoma

Posted: Jun 22, 2017

New clinical trial studies immunotherapy and chemotherapy combination for patients with bile duct cancer for whom surgery is not an option.  Learn more...

New clinical trial studies the addition of immunotherapy to chemotherapy for patients with biliary tract carcinoma

New clinical trial studies therapy for Von Hippel-Lindau disease-associated kidney cancer

Posted: Jun 19, 2017

A new study aims to test targeted therapy in patients with Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma.  Learn more...

New clinical trial studies therapy for Von Hippel-Lindau disease-associated kidney cancer

New clinical trial studies a new drug for mesothelin-positive lung cancer

Posted: Jun 15, 2017

A new phase II clinical trial is testing whether a new drug, anetumab ravtansine, can shrink tumors in mesothelin-positive lung cancer and is now recruiting patients.  Learn more...

New clinical trial studies a new drug for mesothelin-positive lung cancer

New clinical trial studies the immunotherapy drug pembrolizumab in patients with medullary thyroid cancer

Posted: Jun 9, 2017

A new clinical trial studies how the immunotherapy drug pembrolizumab affects patients whose medullary thyroid cancer (MTC) has returned or spread to other areas of the body. Learn more...

New clinical trial studies the immunotherapy drug pembrolizumab in patients with medullary thyroid cancer

Pages